Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26722998 | 0.92 | TAAR1 (0.43) | TAAR1TSHRCTSLCTSBCTSK | |
| SCHEMBL31222606 | 0.88 | CA1 (0.41) | TAAR1TSHRCTSLCTSBCTSK | |
| SCHEMBL31207748 | 0.84 | TAAR1 (0.35) | TAAR1TSHRCTSLCTSBCTSK | |
| SCHEMBL565818 | 0.83 | TMEM97 (0.48) | TAAR1TSHRLMNABCHEACHE | |
| SCHEMBL5606199 | 0.83 | TMEM97 (0.48) | TAAR1TSHRLMNABCHEACHE | |
| SCHEMBL2182755 | 0.83 | TMEM97 (0.48) | TAAR1TSHRLMNABCHEACHE | |
| SCHEMBL26986104 | 0.83 | CA1 (0.43) | APP | |
| SCHEMBL1865729 | 0.82 | TSHR (0.52) | TAAR1TSHRCTSLCTSBCTSK | |
| SCHEMBL23394780 | 0.81 | APP (0.36) | TAAR1TSHRLMNAAPPTMEM97 | |
| SCHEMBL20739380 | 0.81 | ALDH1A1 (0.38) | TAAR1ACHEAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2025-09-11 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117881402-A | Nucleotide and nucleoside therapeutic compositions, combinations, and uses related thereto | 埃默里大学 | 2024-04-12 | — | — | CN | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| EP-0926147-B1 | PROCESS FOR PREPARING 1,3-DIOXOLANE-4-METHANOL COMPOUNDS | DAISO CO LTD (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-6124479-A | Process for the preparation of 1,3-dioxolane-4-methanols | DAISO CO., LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-0926147-A1 | PROCESS FOR PREPARING 1,3-DIOXOLANE-4-METHANOL COMPOUNDS | DAISO CO., LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
| US-5854228-A | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1998-12-29 | — | — | US | disclosed |
| US-5650510-A | VIRICIDES OR ANTITUMOR AGENTS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-07-22 | — | — | US | disclosed |
| EP-0269947-B2 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1996-10-16 | — | — | EP | disclosed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | TAAR1 2852/4885TSHR 3210/4885CTSL 4055/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | TAAR1 2689/4885TSHR 4155/4885CTSL 4880/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | TAAR1 2689/4885TSHR 4155/4885CTSL 4880/4885 |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | NTPCR, TYMP, MTAP | TAAR1 3469/4885TSHR 3042/4885CTSL 3505/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | TAAR1 2689/4885TSHR 4155/4885CTSL 4880/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | TAAR1 4374/4885TSHR 2577/4885CTSL 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.